TY - JOUR
T1 - MicroRNA as Potential Biomarkers of Platelet Function on Antiplatelet Therapy: A Review
AU - Czajka, Pamela
AU - Fitas, Alex
AU - Jakubik, Daniel
AU - Eyileten, Ceren
AU - Gasecka, Aleksandra
AU - Wicik, Zofia
AU - Siller-Matula, Jolanta M.
AU - Filipiak, Krzysztof J.
AU - Postula, Marek
N1 - Funding Information: AG was supported by the PRELUDIUM grant of the Polish National Science Centre (2018/31/N/NZ7/02260). This work was supported by the OPUS of the Polish National Science Centre (2018/31/B/NZ7/01137). Publisher Copyright: © Copyright © 2021 Czajka, Fitas, Jakubik, Eyileten, Gasecka, Wicik, Siller-Matula, Filipiak and Postula. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/4/15
Y1 - 2021/4/15
N2 - MicroRNAs (miRNAs) are small, non-coding RNAs, able to regulate cellular functions by specific gene modifications. Platelets are the major source for circulating miRNAs, with significant regulatory potential on cardiovascular pathophysiology. MiRNAs have been shown to modify the expression of platelet proteins influencing platelet reactivity. Circulating miRNAs can be determined from plasma, serum, or whole blood, and they can be used as diagnostic and prognostic biomarkers of platelet reactivity during antiplatelet therapy as well as novel therapeutic targets in cardiovascular diseases (CVDs). Herein, we review diagnostic and prognostic value of miRNAs levels related to platelet reactivity based on human studies, presenting its interindividual variability as well as the substantial role of genetics. Furthermore, we discuss antiplatelet treatment in the context of miRNAs alterations related to pathways associated with drug response.
AB - MicroRNAs (miRNAs) are small, non-coding RNAs, able to regulate cellular functions by specific gene modifications. Platelets are the major source for circulating miRNAs, with significant regulatory potential on cardiovascular pathophysiology. MiRNAs have been shown to modify the expression of platelet proteins influencing platelet reactivity. Circulating miRNAs can be determined from plasma, serum, or whole blood, and they can be used as diagnostic and prognostic biomarkers of platelet reactivity during antiplatelet therapy as well as novel therapeutic targets in cardiovascular diseases (CVDs). Herein, we review diagnostic and prognostic value of miRNAs levels related to platelet reactivity based on human studies, presenting its interindividual variability as well as the substantial role of genetics. Furthermore, we discuss antiplatelet treatment in the context of miRNAs alterations related to pathways associated with drug response.
KW - antiplatelet therapy
KW - biomarker
KW - miRNA
KW - platelet reactivity
KW - platelets
UR - http://www.scopus.com/inward/record.url?scp=85104969025&partnerID=8YFLogxK
U2 - https://doi.org/10.3389/fphys.2021.652579
DO - https://doi.org/10.3389/fphys.2021.652579
M3 - Review article
C2 - 33935804
SN - 1664-042X
VL - 12
JO - Frontiers in physiology
JF - Frontiers in physiology
M1 - 652579
ER -